<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>KymaThera raises $80M Series A+ led by undisclosed investors.</p><p>Participants in this funding round include various venture capital firms seeking opportunities in the biopharmaceutical sector.</p><p>KymaThera develops precision medicines for genetically defined diseases. The company is led by CEO John Doe.</p><table class="vc-deal-terms"><tbody><tr><th>Company</th><td>KymaThera</td></tr><tr><th>Round</th><td>Series A+</td></tr><tr><th>Amount</th><td>$80M</td></tr><tr><th>Sectors</th><td>precision medicines</td></tr></tbody></table>
</div>
</div>
</div>


<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>KymaThera raises <strong>$80M</strong> Series A+ led by undisclosed investors.</p>
<p>Participants in this funding round include various <a href="/company/venture/">venture</a> capital firms seeking opportunities in the biopharmaceutical sector.</p>
<p>KymaThera develops precision medicines for genetically defined diseases. The company is led by CEO John Doe.</p>
<table class="vc-deal-terms"><tbody>
<tr>
<th>Company</th>
<td>KymaThera</td>
</tr>
<tr>
<th>Round</th>
<td>Series A+</td>
</tr>
<tr>
<th>Amount</th>
<td><strong>$80M</strong></td>
</tr>
<tr>
<th>Sectors</th>
<td>precision medicines</td>
</tr>
</tbody></table>
</div>
</div>
</div>


Kymathera Raises $80M Series A+

Kymathera Raises $80M Series A+ | Traded VC

ABOUT THIS STORY

<div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <div style="font-family: 'Poppins', sans-serif; font-size: 20px;">
  <p>KymaThera raises <strong>$80M</strong> Series A+ led by undisclosed investors.</p>
<p>Participants in this funding round include various <a href="/company/venture/">venture</a> capital firms seeking opportunities in the biopharmaceutical sector.</p>
<p>KymaThera develops precision medicines for genetically defined diseases. The company is led by CEO John Doe.</p>
<table class="vc-deal-terms"><tbody>
<tr>
<th>Company</th>
<td>KymaThera</td>
</tr>
<tr>
<th>Round</th>
<td>Series A+</td>
</tr>
<tr>
<th>Amount</th>
<td><strong>$80M</strong></td>
</tr>
<tr>
<th>Sectors</th>
<td>precision medicines</td>
</tr>
</tbody></table>
</div>
</div>
</div>

Kymathera Raises $80M Series A+

ABOUT THIS STORY

It'sugar Raises $8M From Second Avenue Capital Partners

Benchmark Energy Raises $47.5M From Cibolo Energy Partners

Authors First Raises $10M Seed

Company	KymaThera
Round	Series A+
Amount	$80M
Sectors	precision medicines

Kymathera Raises $80M Series A+

ABOUT THIS STORY

More articles

It'sugar Raises $8M From Second Avenue Capital Partners

Benchmark Energy Raises $47.5M From Cibolo Energy Partners

Authors First Raises $10M Seed